IPO Year:
Exchange: NASDAQ
Fastest customizable press release news feed in the world
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim") announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon "Poster of Distinction" award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD). The Company's award-winning research showcased a physiologically relevant system built from primary human cells derived from both healthy donors and patients with Ulcer
8-K - VivoSim Labs, INC. (0001497253) (Filer)
10-Q - VivoSim Labs, INC. (0001497253) (Filer)
10-K/A - VivoSim Labs, INC. (0001497253) (Filer)
10-K - VivoSim Labs, INC. (0001497253) (Filer)
8-K - VivoSim Labs, INC. (0001497253) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - VivoSim Labs, INC. (0001497253) (Issuer)
3 - VivoSim Labs, INC. (0001497253) (Issuer)
Live Leadership Updates
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players